Pfizer's new migraine drug has been approved for market launch. Lilly and Novartis Same Target Injection have been approved successively
终究未留
发表于 2024-1-26 20:03:07
1274
0
0
Today (January 26th), Pfizer announced that its new generation of specific migraine treatment drug, Rimezepam orally disintegrating tablets, has been approved by the National Medical Products Administration (NMPA) of China for the acute treatment of migraines in adults with or without aura.
Pfizer's official WeChat official account
According to a Pfizer press release, this is a calcitonin gene related peptide (CGRP) receptor antagonist that uses orally disintegrating tablet technology. It can block key pathways related to the onset of migraine, quickly and continuously relieve headaches and related accompanying symptoms. It is easy to take and has no contraindications to cardiovascular diseases.
Rimezepam orally disintegrating tablets are the first oral CGRP receptor antagonist to show positive results in a key trial in China. In this study, patients achieved the common primary endpoint of pain and most troubled symptom relief after a single oral dose of 75mg of medication for 2 hours. Patients can quickly relieve pain and eliminate the most troublesome symptoms within 45 minutes, restore normal function within 60 minutes, and eliminate pain within 90 minutes; For most patients, its sustained therapeutic effect can reach 48 hours.
Remazepam sulfate orally disintegrating tablets were approved for marketing by the US FDA in 2020 for the acute treatment of adult migraine attacks. In May 2022, Pfizer acquired Biohaven for approximately $11.6 billion to expand its migraine product pipeline, thereby acquiring this product.
Migraine is a common chronic disease. The World Health Organization (WHO) lists migraine as one of the top 10 most disabling internal medicine diseases. A reporter from the Daily Economic News noticed that the orally disintegrating tablets of remizepam sulfate are not the only new migraine medication recently launched.
On the 9th of this month, Lilly Galcanezumab injection was approved for sale in China to prevent adult onset migraines.
Galcanezumab is a fully human monoclonal antibody developed by Eli Lilly targeting calcitonin gene related peptide (CGRP), which has been recognized as a breakthrough therapy by the FDA. CGRP is an effective vasodilator neuropeptide, whose release levels significantly increase during migraine attacks. Inhibiting the activity of CGRP and its receptor (CGRPR) can alleviate headaches and prevent migraine attacks.
As of November 2023, a total of 8 migraine drugs targeting CGRP have been approved for marketing worldwide, including Remdesipam Sulfate orally disintegrating tablets and Lilly Galcanezumab. Among them, Anjin& Novartis Pharmaceuticals also approved the marketing of its Irenazumab in September last year by the National Medical Products Administration. It is the first fully human monoclonal antibody drug approved in China that targets the calcitonin gene related peptide (CGRP) receptor, requiring monthly injections to prevent adult migraines.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Johnson&Johnson's drug Zebaike has been approved in China
- Pfizer Beijing R&D Center settles in BioPark, Beijing Medical Innovation Park
- Lilly's Alzheimer's disease drug Kisunla approved for sale in the UK
- Lilly's Alzheimer's disease drug Kisunla approved for sale in the UK
- Pfizer will make an appearance at the 7th CIIE and make a commitment to its development for the next five years
- Pfizer's innovative targeted therapy drug Taizena has been approved in China
- Exhibits become commodities in seconds! Prostate cancer new drug approved in China, Pfizer Wang Yu: promoting China's new drug market to synchronize with the global market
- Exploring the CIIE | New products from Sinogen, Roche, and Pfizer become highlights of the CIIE
- Pfizer plans to sell hospital drug division, company responds
- After closing factories and laying off employees, Pfizer is reportedly considering selling its hospital drug division
-
知名做空机构香橼研究(Citron Research)周四(11月21日)在社交媒体平台X上发布消息称,该公司已决定做空“比特币大户”微策略(Microstrategy)这家公司,并认为该公司已经将自己变身成为一家比特币投资基金 ...
- caffycat
- 昨天 11:18
- 支持
- 反对
- 回复
- 收藏
-
每经AI快讯,11月20日,文远知行宣布旗下自动驾驶环卫车S6与无人扫路机S1分别在新加坡滨海湾海岸大道与滨海艺术中心正式投入运营。据介绍,这是新加坡首个商业化运营的自动驾驶环卫项目。 ...
- star8699
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
上证报中国证券网讯(记者王子霖)11月20日,斗鱼发布2024年第三季度未经审计的财务报告。本季度斗鱼依托丰富的游戏内容生态,充分发挥主播资源和新业务潜力,持续为用户提供高质量的直播内容及游戏服务,进一步 ...
- goodfriendboy
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
人民网北京11月22日电 (记者栗翘楚、任妍)2024广州车展,在新能源汽车占据“半壁江山”的同时,正加速向智能网联新能源汽车全面过渡,随着“端到端”成为新宠,智能驾驶解决方案成为本届广州车展各大车企竞 ...
- 3233340
- 昨天 17:06
- 支持
- 反对
- 回复
- 收藏